Diphtheria
Methodology & AI Transparency ⓘ
Diphtheria Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Diphtheria is a serious bacterial infection.
- 2 Real-world patient consensus: Federal ICD-10-CM code A49.5 categorizes Diphtheria under Bacterial, Viral & Fungal Infections.
- 3 Typical cash cost range: Differential triage of Diphtheria (A49.5) utilizes antimicrobial stewardship (narrow-spectrum in Diphtheria (A49.5: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Follow-up benchmark in Diphtheria: maintaining Targeted PCR / in Diphtheria (A49.5: Culture & Sensitivity) within Pathogen clearance / negative test (A49.5).
Ask our AI Specialists anything about Diphtheria
What Is Diphtheria?
Diphtheria is a serious bacterial infection. You can catch it from a person who has the infection and coughs or sneezes. You can also get infected by coming in contact with an object, such as a toy, that has bacteria on it. Diphtheria usually affects the nose and throat. Symptoms include: Sore throat Swollen glands in the neck Fever Weakness Your doctor will diagnose it based on your signs and symptoms and a lab test. Getting treatment for diphtheria quickly is important. If your doctor suspects that you have it, you'll start treatment before the lab tests come back. Treatment is with antibiotics.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Diphtheria (A49.5) features pathogen-associated molecular pattern in Diphtheria (A49.5: (PAMP) innate immune). Cross-referenced with NIH MeSH (Diphtheria), therapeutic stabilization in infections & antivirals is verified against Complete Blood Count in Diphtheria (A49.5: (WBC & Differential)).
Common Symptoms & Clinical Signs
- • Swollen glands in the neck
- • Presentation of Diphtheria (A49.5): acute fever, chills, in Diphtheria (A49.5: malaise, and myalgias)
- • Secondary Diphtheria clinical sign: sore throat, productive in Diphtheria (A49.5: cough, sinus/ear pain,)
- • Symptom flares in Diphtheria correlating with Targeted PCR / in Diphtheria (A49.5: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (A49.5)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Diphtheria Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A49.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Targeted PCR / in Diphtheria (A49.5: Culture & Sensitivity) | Pathogen clearance / negative test (A49.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Diphtheria (A49.5: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (A49.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Diphtheria (A49.5: Procalcitonin) | Resolution to baseline (A49.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diphtheria
Treatment selection for Diphtheria depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diphtheria)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with: What a 1,212-Participant Study Found Olgotrelvir as a single-agent treatment significantly improved symptom recovery. NEJM evidence • 2024-06-15 • Phase III Randomized Trial | N = 1,212 | 96/100 | PMID 38804790 ↗ |
| Protecting Teens and Young Adults From Meningitis: Inside a 2,080-Person Vaccine Trial This study supports the safety profile of MenACYW-TT in infants and toddlers aged ≥ 6 weeks. Human vaccines & immunotherapeutics • 2026-12-15 • Phase III Randomized Trial | N = 2,080 | 90/100 | PMID 42642862 ↗ |
| New Insights on Mutual effects on safety and immunogenicity of combined vaccination with: What a 1,110-Participant Study Found Incidence of AEs in P+DTP group was lower than P-DTP group and slightly higher than DTaP group. Human vaccines & immunotherapeutics • 2026-12-15 • Phase III Randomized Trial | N = 1,110 | 90/100 | PMID 42546220 ↗ |
| New Insights on Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in: What a 218-Participant Study Found The BR-TD-1001 satisfied the immunological non-inferiority criterion against diphtheria and tetanus, with a clinically acceptable safety profile. Journal of Korean medical science • 2021-12-20 • Phase III Randomized Trial | N = 218 | 88/100 | PMID 34931494 ↗ |
| New Insights on Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with: What a 360-Participant Study Found Results indicated that there is non-interference of MMR vaccine with Vi-DT and Vi-DT conjugate vaccine could be considered as an addition to the EPI schedule among children at risk of contracting typhoid. Vaccine • 2022-09-22 • Phase III Randomized Trial | N = 360 | 87/100 | PMID 36064672 ↗ |
Diphtheria Patient Community & “People Like Me” Threads
Filter Diphtheria community threads and patient logs by age, biological sex, dosage, and treatment duration.